Accepted answer
Start with the presentation, because the discriminating feature is a characteristic pain pattern rather than any laboratory value.
That pattern is quite different from the fullness, intermittent nausea and cramping of ordinary gastrointestinal effects in this class, which is why the description carries the diagnostic weight.
Gastrointestinal adverse events, indicative pooled rates
| Event | Active arm | Placebo arm | Timing |
|---|
| Nausea | 40–45 % | 15–20 % | Peaks 1–2 wk after each step |
| Vomiting | 15–25 % | 5–8 % | Follows nausea |
| Diarrhoea | 20–30 % | 10–15 % | Early, variable |
| Constipation | 20–25 % | 8–12 % | Later onset, persistent |
| Discontinuation for GI events | 4–7 % | 1–2 % | Mostly during escalation |
Ranges span agents and doses; read the specific prescribing information for a specific figure.
Put another way, routine monitoring of pancreatic enzymes is explicitly not recommended, because asymptomatic elevations are common in this class and lead to investigation without benefit.
Guidance against routine pancreatic enzyme monitoring in this class rests on the frequency of asymptomatic elevation and the poor specificity that follows.
A raised lipase without the clinical picture is not a diagnosis, and chasing one causes harm through investigation.
That pattern is an emergency. Everything else in this tag is background.